CA2989740A1 — Stimulators and/or activators of soluble guanylate cyclase (sgc) in combination with an inhibitor of neutral endopeptidase (nep inhibitor) and/or an angiotensin aii antagonist and the use thereof
Assigned to Bayer Pharma AG · Expires 2017-01-26 · 9y expired
What this patent protects
The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonist and the use thereof for treatment and/or prophylaxis of cardiovascular disorders, for example heart…
USPTO Abstract
The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonist and the use thereof for treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with maintained ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, pulmonary disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (for example end organ damage affecting the brain, kidney or heart).
Drugs covered by this patent
- Adempas (RIOCIGUAT) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.